Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

AtaiBeckley Inc. - Common Stock (NQ:ATAI)

4.900 +0.870 (+21.59%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 20, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	47,138,012
Open	5.030
Bid (Size)	5.000 (4,300)
Ask (Size)	5.020 (700)
Prev. Close	4.030
Today's Range	4.800 - 5.510
52wk Range	1.290 - 6.750
Shares Outstanding	166,010,476
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Why AtaiBeckley Stock Surged Today ↗

Today 22:11 EDT

President Trump wants to fast-track psychedelic research.

Via The Motley Fool

Small-Cap Medical Stocks: ATAI, CMPS, NDRA, PBM in Focus as U.S. Policy Accelerates Psychedelic Research

Today 16:39 EDT

Via AB Newswire

Performance

YTD	+26.6%	+26.6%
1 Month	+44.5%	+44.5%
3 Month	+27.3%	+27.3%
6 Month	-23.7%	-23.7%
1 Year	+245.1%	+245.1%

More News

This 4/20, Wall Street Is Betting on More Than Marijuana ↗

Today 15:05 EDT

Via MarketBeat

AtaiBeckley Stock Skyrockets After Cantor Fitzgerald's Overweight Rating ↗

Today 14:36 EDT

Via Benzinga

What's going on in today's session ↗

Today 12:30 EDT

Via Chartmill

Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar ↗

Today 11:27 EDT

Via The Motley Fool

These stocks are gapping in today's session ↗

Today 10:30 EDT

Via Chartmill

Top movers in Monday's pre-market session ↗

Today 8:30 EDT

Via Chartmill

The 15-Minute Breakthrough: A Deep Dive into GH Research (GHRS) and the Future of Rapid-Acting Psychedelics

March 26, 2026

Via Finterra

AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst

March 24, 2026

From AtaiBeckley Inc.

Via GlobeNewswire

BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation

March 17, 2026

From AtaiBeckley Inc.

Via GlobeNewswire

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day

March 10, 2026

From AtaiBeckley Inc.

Via GlobeNewswire

ENDRA Life Sciences (NASDAQ: NDRA): The GLP-1 Healthcare Boom Offering Tremendous Opportunity Watch HIMS, ANTX, ATAI, PURR Now!

March 09, 2026

Via AB Newswire

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update

March 06, 2026

From AtaiBeckley Inc.

Via GlobeNewswire

AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression

March 03, 2026

From AtaiBeckley N.V.

Via GlobeNewswire

AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder

February 26, 2026

From AtaiBeckley N.V.

Via GlobeNewswire

AtaiBeckley To Host Virtual Investor Day on March 6, 2026

February 20, 2026

From AtaiBeckley N.V.

Via GlobeNewswire

AtaiBeckley Appoints Michael Faerm as Chief Financial Officer

February 19, 2026

From AtaiBeckley N.V.

Via GlobeNewswire

AtaiBeckley To Participate in Upcoming Investor Conferences

February 17, 2026

From AtaiBeckley N.V.

Via GlobeNewswire

High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 ↗

January 19, 2026

Via MarketBeat

AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation

January 16, 2026

From AtaiBeckley N.V.

Via GlobeNewswire

AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference

January 08, 2026

From AtaiBeckley N.V.

Via GlobeNewswire

GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatment ↗

January 05, 2026

Via Stocktwits

AtaiBeckley Completes Redomiciliation to the United States

December 30, 2025

From AtaiBeckley N.V.

Via GlobeNewswire

AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)

December 23, 2025

From AtaiBeckley N.V.

Via GlobeNewswire

Frequently Asked Questions

Is AtaiBeckley Inc. - Common Stock publicly traded?

Yes, AtaiBeckley Inc. - Common Stock is publicly traded.

What exchange does AtaiBeckley Inc. - Common Stock trade on?

AtaiBeckley Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for AtaiBeckley Inc. - Common Stock?

The ticker symbol for AtaiBeckley Inc. - Common Stock is ATAI on the Nasdaq Stock Market

What is the current price of AtaiBeckley Inc. - Common Stock?

The current price of AtaiBeckley Inc. - Common Stock is 4.900

When was AtaiBeckley Inc. - Common Stock last traded?

The last trade of AtaiBeckley Inc. - Common Stock was at 04/20/26 04:00 PM ET

What is the market capitalization of AtaiBeckley Inc. - Common Stock?

The market capitalization of AtaiBeckley Inc. - Common Stock is 813.45M

How many shares of AtaiBeckley Inc. - Common Stock are outstanding?

AtaiBeckley Inc. - Common Stock has 813M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.